Medical uses

Breast cancer

Letrozole is indicated for adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer; extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy; first and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer.

Letrozole is approved by the United States Food and Drug Administration

1.Previous
3.Next